Mendus AB
IMMU.STDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Intuvax (INN: ilixadencel)
Renal Cell Carcinoma, Metastatic
DCP-001
Acute Myeloid Leukemia (AML)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Intuvax (INN: ilixadencel) | Phase 2 | Renal Cell Carcinoma, Metastatic | - | - |
DCP-001 | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
Frequently asked questions
What is in Mendus AB's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Mendus AB's (IMMU.ST) pipeline across Phase 2. Its lead program is Intuvax (INN: ilixadencel) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mendus AB's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Mendus AB (IMMU.ST) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IMMU.ST biotech catalysts?→
Add IMMU.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mendus AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.